동물 위식도 역류질환 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 동물별, 모드별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Animal GERD Market Size & Trends:

The global animal gastroesophageal reflux disease market size was valued at USD 3.33 billion in 2024 and is expected to grow at a CAGR of 7.7% from 2025 to 2030. The market is primarily driven by rising prevalence of gastrointestinal diseases such as gastroesophageal reflux disease (GERD) in animals, particularly in dogs, increasing humanization of pets, and ongoing advancements in veterinary diagnostics and treatments. Furthermore, poor diet or abrupt changes in diet is one of the factors contributing to GERD in pets. Overweight pets are more likely to develop GERD. For instance, according to a June 2024 study by ScienceDirect, the prevalence of obesity in dogs was estimated to be 35%. Certain breeds, especially brachycephalic (short-nosed) breeds, are more susceptible to GERD. However, younger pups and brachycephalic (flat-faced) dogs are at greater risk.

In addition, the trend towards overall pet health and wellness, coupled with development of specialized diets, is driving demand for products that manage gastrointestinal issues. Economic factors, such as rising disposable incomes and the growth of pet insurance, are also enabling pet owners to afford comprehensive veterinary care. According to a recent survey conducted by USA Today, a significant proportion of Americans are dedicating a substantial portion of their monthly income to pet care. A 26% of respondents spend between USD 51 and USD 100 per month on their dogs, while an equal percentage 26% allocate between USD 101 and USD 250 for their canine companions needs. In some cases, the total cost of dog ownership can reach as high as USD 5,000. Notably, two-thirds of respondents (66%) reported having to sacrifice their own needs to keep up with the rising expenses associated with pet ownership. Some individuals have resorted to taking out loans or seeking financial assistance to cover the costs of caring for their pets.

The market is further characterized by advancements in technology that have significantly improved the ability to detect and manage these conditions. Veterinarians now have access to more sophisticated imaging techniques, such as fluoroscopy and high-resolution endoscopy, which allow for real-time visualization of the esophagus and stomach during swallowing and digestion. Additionally, esophageal pH monitoring and impedance testing have been adapted for use in pets, providing valuable data on acid exposure and reflux events. Biomarker analysis, including measurement of pepsin in saliva or respiratory secretions, is emerging as a non-invasive diagnostic tool. These developments, combined with an improved understanding of breed-specific predispositions and risk factors, have enhanced early detection and treatment strategies for GERD in dogs and cats, leading to better outcomes and improved quality of life for affected animals.

Governments often fund collaborative research programs that bring together universities, research institutions, and private companies to tackle veterinary health issues, including GERD. These programs facilitate the sharing of knowledge and resources to accelerate advancements. Governments sponsor campaigns to raise awareness about GERD in animals among pet owners and veterinarians. These campaigns aim to educate the public on recognizing symptoms and seeking timely veterinary care.

Global Animal Gastroesophageal Reflux Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global animal gastroesophageal reflux disease market report based on product, animal, mode, route of administration, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Diagnostics
  • Laboratory Tests
  • Veterinary Imaging
  • Others
• Treatment
  • Antacids
  • H2 Receptor Blockers
  • Proton Pump Inhibitors (PPIs)
  • Pro-kinetic agents
  • Others
• Others
• Animal Outlook (Revenue, USD Million, 2018 - 2030)
• Companion Animal
  • Dogs
  • Cats
  • Horses
  • Others
• Livestock Animal
  • Cattle
  • Poultry
  • Swine
  • Sheep & Goats
  • Others
• Mode Outlook (Revenue, USD Million, 2018 - 2030)
• OTC
• Prescription
• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
• Oral
• Injectable
• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Veterinary hospitals & clinics
• Retail Pharmacies
• E-commerce
• Regional Outlook (Revenue in USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates And Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis
  • 1.6.2. Global Market: CAGR Calculation
• 1.7. Research Scope and Assumptions
  • 1.7.1. List of Secondary Sources
  • 1.7.2. List of Primary Sources
  • 1.7.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Animal Gastroesophageal Reflux Disease (GERD) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Increasing Pet Population & Expenditure
    • 3.2.1.2. Rising Prevalence Of Gastroesophageal Reflux Disease (GERD) in Animals
    • 3.2.1.3. Growing Advancement In Veterinary Medicine
    • 3.2.1.4. Increase in RD Expenditure
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Stringent Regulatory Requirements
    • 3.2.2.2. Lack of awareness in developing regions.
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Animal Gastroesophageal Reflux Disease (GERD) Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal landscape
• 3.4. Covid-19 Analysis
• 3.5. Estimated Pet Population, by key countries

Chapter 4. Animal Gastroesophageal Reflux Disease (GERD) Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Animal Gastroesophageal Reflux Disease (GERD) Market Movement Analysis
• 4.3. Global Animal Gastroesophageal Reflux Disease (GERD) Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Diagnostics
  • 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Laboratory Tests
    • 4.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Veterinary Imaging
    • 4.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Treatment
  • 4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Antacids
    • 4.5.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. H2 Receptor Blockers
    • 4.5.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Proton Pump Inhibitors (PPIs)
    • 4.5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.5. Pro-kinetic Agents
    • 4.5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.6. Other treatments
    • 4.5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Animal Gastroesophageal Reflux Disease (GERD) Market: Animal Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Animal Gastroesophageal Reflux Disease (GERD) Market Movement Analysis
• 5.3. Global Animal Gastroesophageal Reflux Disease (GERD) Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
• 5.4. Companion Animal
  • 5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Dogs
    • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Cats
    • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Horses
    • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.5. Other Companion Animal
    • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Production Animal
  • 5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Cattle
    • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Poultry
    • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. Swine
    • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Sheep & Goats
    • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Other Production Animal
    • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Animal Gastroesophageal Reflux Disease (GERD) Market: Mode Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Animal Gastroesophageal Reflux Disease (GERD) Market Movement Analysis
• 6.3. Global Animal Gastroesophageal Reflux Disease (GERD) Market Size & Trend Analysis, by Mode, 2018 to 2030 (USD Million)
• 6.4. OTC
  • 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Prescription
  • 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Animal Gastroesophageal Reflux Disease (GERD) Market: Route of Administration Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Animal Gastroesophageal Reflux Disease (GERD) Market Movement Analysis
• 7.3. Global Animal Gastroesophageal Reflux Disease (GERD) Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 7.4. Oral
  • 7.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. Injectable
  • 7.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Animal Gastroesophageal Reflux Disease (GERD) Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Animal Gastroesophageal Reflux Disease (GERD) Market Movement Analysis
• 8.3. Global Animal Gastroesophageal Reflux Disease (GERD) Market Size & Trend Analysis, Distribution Channel, 2018 to 2030 (USD Million)
• 8.4. Veterinary Hospitals & Clinics
  • 8.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.5. Retail Pharmacies
  • 8.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.6. E-Commerce
  • 8.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Animal Gastroesophageal Reflux Disease (GERD) Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030 North America
• 9.3. North America
  • 9.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. U.K.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. U.K. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. Japan
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.6. Australia
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.7. Thailand
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.7. Middle East and Africa
  • 9.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.3. South Africa
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Market Participant Categorization
• 10.2. Company Market Position Analysis/ Heat Map Analysis
• 10.3. Estimated Company Market Share Analysis, 2023
• 10.4. Strategy Mapping
  • 10.4.1. Mergers & Acquisitions
  • 10.4.2. Partnerships & Collaborations
  • 10.4.3. Others
• 10.5. Company Profiles
  • 10.5.1. McNeil Consumer Pharmaceuticals Co.
    • 10.5.1.1. Participant's Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. Boehringer Ingelheim International GmbH.
    • 10.5.2.1. Participant's Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Zoetis
    • 10.5.3.1. Participant's Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. Merck & CO., Inc.
    • 10.5.4.1. Participant's Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. BioZyme, Inc.
    • 10.5.5.1. Participant's Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Ceva
    • 10.5.6.1. Participant's Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Bio-Rad Laboratories, Inc.
    • 10.5.7.1. Participant's Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Hill's Pet Nutrition, Inc.
    • 10.5.8.1. Participant's Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic Initiatives
  • 10.5.9. Annamaet Petfoods Inc.
    • 10.5.9.1. Participant's Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Strategic Initiatives
  • 10.5.10. Blue Buffalo Co., Ltd.
    • 10.5.10.1. Participant's Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Strategic Initiatives

Chapter 11. Key Takeaways